Dicoumarol

BLOOD AND BLOOD FORMING ORGANS

Key facts

Dicoumarol is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 1944. DrugCentral lists 11 molecular targets, including Nqo1, NQO1 and GPR35. Recorded indications include Cerebral embolism, Myocardial infarction, Prevention of Cerebral Thrombosis and Thromboembolic disorder.

• Approval status: ofm (first approved 1944 by the FDA).
• Molecular targets: Nqo1, NQO1, GPR35 and CYP2C9 (11 listed in DrugCentral).
• Indications: Cerebral embolism, Myocardial infarction, Prevention of Cerebral Thrombosis, Thromboembolic disorder and Thrombosis.
• ATC code: B01AA01 (Vitamin K antagonists).
• Molecular formula: C19H12O6; molecular weight 336.30 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (5)

• Cerebral embolism
• Myocardial infarction
• Prevention of Cerebral Thrombosis
• Thromboembolic disorder
• Thrombosis

Off-label uses (1)

• Prosthetic replacement of heart valve

Contraindications (58)

• Alcoholism
• Anemia
• Bacterial endocarditis
• Bleeding
• Bleeding Risk Associated with Vitamin-K-Epoxide Reductase (Warfarin-Sensitive) Gene
• Blood coagulation disorder
• Cerebral hemorrhage
• Cerebrovascular disease
• Cholesterol Embolism
• Chronic diarrhea
• Disease of liver
• Disorder of connective tissue
• Dissection of aorta
• Eclampsia in pregnancy
• Edema
• Fatty stool
• Fever
• Gangrene
• Gastrointestinal hemorrhage
• Gastrointestinal ulcer
• Genitourinary tract hemorrhage
• Heparin-induced thrombocytopenia
• Hepatic failure
• Hyperlipidemia
• Hypertensive disorder
• Hypertensive urgency
• Hyperthyroidism
• Hypothyroidism
• Impaired renal function disorder
• Indwelling Vascular Catheter
• + 28 more

Mechanism & targets

Molecular targets (11)

Target	Gene	Action	Activity
NAD(P)H dehydrogenase [quinone] 1	Nqo1	unknown	Ki 9.00
NAD(P)H dehydrogenase [quinone] 1	NQO1	unknown	Ki 8.00
G-protein coupled receptor 35	GPR35	unknown	Ki 7.41
Cytochrome P450 2C9	CYP2C9	unknown	Ki 5.97
Proprotein convertase subtilisin/kexin type 7	PCSK7	unknown	IC50 5.89
Vitamin K epoxide reductase complex subunit 1	VKORC1	inhibitor	IC50 5.51
Aldose reductase	Akr1b1	unknown	IC50 5.39
Mitogen-activated protein kinase 1	MAPK1	unknown	IC50 5.35
Urease	—	unknown	IC50 4.82
Enoyl-[acyl-carrier-protein] reductase [NADH]	fabI	unknown	IC50 4.33
ATP phosphoribosyltransferase	hisG	unknown	Ki 4.22

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1944-07-31	FDA	—	ABBVIE

ATC classification

ATC code	Therapeutic hierarchy
B01AA01	BLOOD AND BLOOD FORMING ORGANS › ANTITHROMBOTIC AGENTS › ANTITHROMBOTIC AGENTS › Vitamin K antagonists

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Dicoumarol is on its molecule page.

• Molecular formula: C₁₉H₁₂O₆
• Molecular weight: 336.30 g/mol
• CAS number: 66-76-2
• InChIKey: DOBMPNYZJYQDGZ-UHFFFAOYSA-N
• PubChem CID: 54676038

OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=CC=CC=C12

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Dicoumarol used for?

DrugCentral lists the following indications for Dicoumarol: Cerebral embolism, Myocardial infarction, Prevention of Cerebral Thrombosis, Thromboembolic disorder and Thrombosis.

How does Dicoumarol work?

Its molecular targets in DrugCentral include Nqo1, NQO1, GPR35 and CYP2C9.

When was Dicoumarol first approved?

Dicoumarol was first approved by the FDA in 1944.

What is the chemical formula of Dicoumarol?

Dicoumarol has the molecular formula C19H12O6 and a molecular weight of 336.30 g/mol.

Sources

• DrugCentral drug card 867 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1466 — compound record and bioactivity
• PubChem CID 54676038 — chemical identifiers
• DrugBank DB00266 — drug record
• FDA UNII 7QID3E7BG7 — substance identity
• DailyMed: FDA labels for Dicoumarol — current prescribing information (label search)
• UniProt P15559 (NQO1) — target protein
• UniProt Q9HC97 (GPR35) — target protein
• UniProt P11712 (CYP2C9) — target protein
• UniProt Q16549 (PCSK7) — target protein
• UniProt Q9BQB6 (VKORC1) — target protein
• UniProt P28482 (MAPK1) — target protein

How this page is built: methodology · editorial policy & corrections.